Cannabis
Cannabis or Cannabinoids for management of chronic noncancer pain: best practice advice from the American College of Physicians.
Ann Intern Med 2025;178:714-724
Efficacy of cannabinoids for the prophylaxis of chemotherapy-induced nausea and vomiting—a systematic review and meta-analysis.
Support Care Cancer 2025;33:193
The impact of cannabis on immune checkpoint inhibitor therapy:a systematic review of immunomodulator effects of cannabis in patients with and without cancer.
Support Care Cancer 2025;33:166
MASCC guideline: cannabis for cancer-related pain and risks of harms and adverse events.
Support Care Cancer 2023;31:202. Note: Only abstract content is available.
MASCC guidelines: cannabis for psychological symptoms including insomnia, anxiety and depression.
Support Care Cancer 2023;31:176. Note: Only abstract content is available.
Comments from Dr. Abrahm:
MASCC guidelines 2023: counsel against its use for psychological symptoms in cancer until the evidence improves, or cancer pain.
Cannabis Use in Patients with Cancer: A Clinical Review
J Oncol Pract 2022; 18:743-752.
Comments from Dr. Abrahm:
While cannabis is not indicated to treat cancer, the Guidelines state that it “may improve refractory, chemotherapy-induced nausea and vomiting when added to guideline-concordant anti-emetic regimens.” More research for other indications is urged, as whether it improves other symptoms is uncertain. CBD at 300 mg a day or more causes reversible liver enzyme elevations and may interfere with buprenorphine and tacrolimus metabolism.
Cannabis and cannabinoids in adults with cancer: Guideline Q & A
J Clin Oncol Pract 2024;20:667-770.
Comments from Dr. Abrahm:
While cannabis is not indicated to treat cancer, the Guidelines state that it “may improve refractory, chemotherapy-induced nausea and vomiting when added to guideline-concordant anti-emetic regimens.” More research for other indications is urged, as whether it improves other symptoms is uncertain. CBD at 300 mg a day or more causes reversible liver enzyme elevations and may interfere with buprenorphine and tacrolimus metabolism.
Cannabis and cannabinoids in adults with cancer: ASCO guideline.
J Clin Oncol 2024;42:1575-1593.
Dr. Abrahm's Book
Dr. Abrahm is the author of four comprehensive editions on supportive and palliative care for patients with cancer, the first published in 2000 and the latest in 2022.
Her extensive work offers oncologists and other oncology and palliative care clinicians a place to turn to find the most up-to-date evidence-based practices, resources, and practical advice on how to care for patients across the full range of issues they will experience during their illness.
Comments from Dr. Abrahm:
MASCC guidelines 2023: counsel against its use for psychological symptoms in cancer until the evidence improves, or cancer pain.